<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nicotine poisoning (e-cigarettes, tobacco products, plants, and pesticides)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nicotine poisoning (e-cigarettes, tobacco products, plants, and pesticides)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nicotine poisoning (e-cigarettes, tobacco products, plants, and pesticides)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alexander F Barbuto, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James F Wiley, II, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2629107570"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic will discuss nicotine poisoning after exposure to nicotine-containing plants, tobacco products, and concentrated nicotine solutions such as those used in electronic cigarettes (e-cigarettes) and pesticides.</p><p>The clinical diagnosis, manifestations, and management of poisoning by organophosphate or carbamate pesticides and other plants are discussed separately. (See  <a class="medical medical_review" href="/d/html/339.html" rel="external">"Organophosphate and carbamate poisoning"</a> and  <a class="medical medical_review" href="/d/html/6507.html" rel="external">"Potentially toxic plant ingestions in children: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/d/html/16521.html" rel="external">"Toxic plant ingestions in children: Management"</a>.)</p><p class="headingAnchor" id="H3273493836"><span class="h1">NICOTINE-CONTAINING PLANTS AND PRODUCTS</span><span class="headingEndMark"> — </span>Nicotine occurs naturally in tobacco and several other plants and is used commercially in many tobacco and nicotine products:</p><p class="bulletIndent1"><span class="glyph">●</span>The tobacco plant, <em>Nicotiana tabacum</em>, is the source of tobacco for cigarettes, cigars, and chewing tobacco.</p><p></p><p class="bulletIndent1">Other plants containing nicotine-like alkaloids are much less commonly involved in nicotine poisoning. Examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Conium maculatum</em> (poison hemlock)</p><p class="bulletIndent2"><span class="glyph">•</span><em>Lobelia inflata</em> (Indian tobacco) </p><p class="bulletIndent2"><span class="glyph">•</span><em>Baptisia australis</em> (blue wild or blue false indigo)</p><p class="bulletIndent2"><span class="glyph">•</span><em>Laburnum anagyroides</em> (golden chain)</p><p class="bulletIndent2"><span class="glyph">•</span><em>Cytisus laburnum</em> (golden chain tree)</p><p class="bulletIndent2"><span class="glyph">•</span><em>Caulophyllum thalictroides</em> (blue cohosh)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nicotine is also present in patches, gums, lozenges, and liquids for vaporization in e-cigarettes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nicotine and chemically similar neonicotinoids can be used as potent insecticides.</p><p></p><p class="headingAnchor" id="H958306386"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Almost 16,000 cases of nicotine exposure are reported to United States regional poison control centers annually [<a href="#rid1">1</a>]. Cigarettes (approximately 5400 annual cases) and e-cigarettes (approximately 4400 annual cases) account for most United States nicotine exposures [<a href="#rid1">1,2</a>]. The majority of nicotine exposures are exploratory ingestions in young children. However, a significant number arise from attempts at self-harm in adolescents and adults [<a href="#rid1">1,3,4</a>]. Concentrated nicotine solutions, such as those found in e-cigarette refills and pesticides, are the most dangerous [<a href="#rid1">1-3,5,6</a>]. Ingestion of even a small amount of these concentrated liquids can cause serious toxicity. Deaths are rare but have occurred in infants and toddlers [<a href="#rid1">1,2,5</a>].</p><p>By contrast, exposure to nicotine-containing plants (most commonly, the tobacco plant [<em>Nicotiana </em>tabacum]) is infrequent, with approximately 100 annual exposures reported to United States regional poison control centers [<a href="#rid1">1</a>]. Most nicotine-plant exposures result in mild or moderate symptoms. However, selected plants (eg, poison hemlock, <em>Conium maculatum</em>) have rarely been associated with serious toxicity and death [<a href="#rid7">7-10</a>]. (See <a class="local">'Tobacco and other nicotinic plants'</a> below.)</p><p class="headingAnchor" id="H4262545358"><span class="h1">TOXICITY AND TOXICOKINETICS</span></p><p class="headingAnchor" id="H2373804739"><span class="h2">Mechanism of toxicity</span><span class="headingEndMark"> — </span>Nicotine binds to nicotinic acetylcholine receptors (nAChRs), which are present in the brain, the spinal cord (postganglionic sympathetic and parasympathetic neurons), and at the neuromuscular junction [<a href="#rid11">11</a>]. Under normal conditions, acetylcholine is the neurotransmitter at these receptors. The nAChR is a cation ionic channel, which causes cell depolarization when activated. Repeated agonism, however, can lead to functional paralysis of the receptor. As a result, nicotine toxicity classically manifests in a biphasic pattern [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Initial activation with neuronal excitation that produces:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diaphoresis (sympathetic stimulation of the sweat glands)</p><p class="bulletIndent2"><span class="glyph">•</span>Tachycardia, hypertension, and pallor (sympathetic stimulation)</p><p class="bulletIndent2"><span class="glyph">•</span>Bronchorrhea, bronchospasm, salivation, vomiting, diarrhea, and miosis (parasympathetic stimulation)</p><p class="bulletIndent2"><span class="glyph">•</span>Skeletal muscle fasciculations (neuromuscular excitation)</p><p class="bulletIndent2"><span class="glyph">•</span>Hyperactivity, agitation, tremor, and/or seizures (brain excitation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Marked inhibition causing:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bradycardia, arrhythmias, and hypotension, which can progress to asystole</p><p class="bulletIndent2"><span class="glyph">•</span>Skeletal muscle paralysis</p><p class="bulletIndent2"><span class="glyph">•</span>Apnea</p><p class="bulletIndent2"><span class="glyph">•</span>Coma</p><p></p><p>Nicotine and neonicotinoids (found in pesticides) differ in their behavior at the nAChr. Nicotine can behave as a full or partial agonist [<a href="#rid11">11</a>]; neonicotinoids can act as agonists, partial agonists, or antagonists [<a href="#rid12">12</a>]. In general, neonicotinoid exposures are less likely to cause major toxicity except after large intentional ingestions. (See <a class="local">'Neonicotinoids'</a> below.)</p><p>Although also causing neuromuscular dysfunction, organophosphates inhibit acetylcholinesterase, causing a buildup of excess acetylcholine, leading to repeated depolarization at the neuromuscular junction  (<a class="graphic graphic_figure graphicRef78828" href="/d/graphic/78828.html" rel="external">figure 1</a>) rather than direct binding of nicotinic anticholinergic receptors. (See  <a class="medical medical_review" href="/d/html/339.html" rel="external">"Organophosphate and carbamate poisoning", section on 'Mechanism of action'</a>.)</p><p class="headingAnchor" id="H1118021489"><span class="h2">Toxic dose</span><span class="headingEndMark"> — </span>Toxicity depends upon the route of exposure:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ingestion</strong> – The estimated toxic and lethal ingested nicotine doses for children and adults are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Child [<a href="#rid13">13</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Toxic dose: 0.1 mg/kg</p><p class="bulletIndent3"><span class="glyph">-</span>Minimum lethal dose: 1 mg/kg</p><p></p><p class="bulletIndent2">A total dose of 1 to 2 mg of nicotine is potentially toxic in children. In children, doses as small as 2 mg (approximately 0.1 mg/kg) have produced symptoms such as lethargy or weakness [<a href="#rid14">14</a>]. The table provides an estimated toxic ingested dose for common tobacco and nicotine products  (<a class="graphic graphic_table graphicRef138391" href="/d/graphic/138391.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2">An estimated nicotine dose of &lt;0.01 mg/kg typically results in minimal or no symptoms [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adult [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Toxic dose in adults naïve to nicotine: 4 to 7 mg</p><p class="bulletIndent3"><span class="glyph">-</span>Minimum lethal dose: 60 mg</p><p></p><p class="bulletIndent2">In adults, 60 mg is an oft-cited lethal dose. However, this threshold is debated based upon survival of adult patients who have measured plasma concentrations after e-cigarette liquid ingestion that are up to 10 times higher than the expected concentration after ingestion of 60 mg of nicotine [<a href="#rid5">5,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermal (liquid nicotine) </strong>– Dermal exposure to concentrated nicotine liquid (eg, e-cigarette solutions, nicotine-containing pesticides, nicotine dermal patches, or exposure to wet tobacco plants [green tobacco sickness]) has the potential to cause poisoning, especially if exposure is prolonged [<a href="#rid4">4,15,17-21</a>]. Severe poisoning and death have occurred with prolonged exposure to multiple transdermal nicotine patches in adults [<a href="#rid15">15,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular (liquid nicotine)</strong> – Based upon isolated reports of inadvertent ocular administration of e-cigarette solutions, ocular nicotine liquid exposure causes eye redness, pain, and local irritation; systemic effects have not been described [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhalation</strong> – Cigarette and e-cigarette inhalation exposures account for a small minority of nicotine exposures. Cigarette smoking in patients with no prior nicotine exposure can cause self- limited cough, nausea, and vomiting [<a href="#rid23">23</a>]. Because of the higher concentration of nicotine during e-cigarette inhalation, more serious poisoning is possible. For example, in a study of 10 e-cigarette inhalational exposures in children reported to a regional poison control center, excessive vaping from an e-cigarette was associated with vomiting, marked tachycardia, lethargy, seizures, and hallucinations in two adolescents [<a href="#rid21">21</a>]. No symptoms occurred in a three-year-old child who took one or two "drags" from the parent's e-cigarette.</p><p></p><p>The clinical features of poisoning are described below. (See <a class="local">'Toxicity by nicotine source'</a> below and <a class="local">'Clinical features of poisoning'</a> below.)</p><p class="headingAnchor" id="H273134616"><span class="h2">Toxicokinetics</span><span class="headingEndMark"> — </span>Toxicokinetics for nicotine are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absorption</strong> – Nicotine absorption is rapid by all routes. Peak concentration is reached within minutes by inhalation or mucosal exposure.</p><p></p><p class="bulletIndent1">Because nicotine is a weak base (pKa = 8.0), it is more readily absorbed from basic or neutral environments than acidic ones. Gastric absorption may be delayed or incomplete. While precise pharmacokinetics following oral overdose are not well described, peak plasma concentrations were reached one to two hours following oral administration of a nicotine-replacement product [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">Dermal absorption can be rapid and varies by nicotine concentration and age [<a href="#rid25">25</a>]. Transdermal nicotine patches are designed to deliver between 0.3 and 0.9 mg per hour, though pharmacokinetic studies have not been evaluated in children. The skin may also serve as a reservoir following patch placement, with 10 percent of total dose being absorbed after removal of a patch in one pharmacokinetic study [<a href="#rid26">26</a>]. Wet tobacco plants or nicotinic pesticides are other potential sources of dermally absorbed nicotine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Volume of distribution and protein binding</strong> – The volume of distribution of nicotine is 2.6 L/kg. It is minimally protein bound (approximately 5 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and half-life</strong> – Metabolism is predominantly hepatic (80 to 90 percent), largely via cytochrome oxidases 2A6 and 2D6 [<a href="#rid27">27</a>]. The remainder of nicotine is metabolized by the lung or kidney.</p><p></p><p class="bulletIndent1">The observed half-life is one to four hours but can be lower in chronic users.</p><p></p><p class="headingAnchor" id="H3007693185"><span class="h3">Onset of toxicity</span><span class="headingEndMark"> — </span>Onset of symptoms after nicotine exposure is frequently rapid but also depends upon the type of exposure:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhalation or mucosal administration</strong> – Inhalation or mucosal administration (such as buccal or rectal) typically has an onset of symptoms within minutes [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ingestion</strong> – Initial symptoms of nausea and/or vomiting often appear within 15 to 30 minutes after ingestion. However, because nicotine is a weak base and has poor absorption in the acidic environment of the stomach, peak blood concentrations may not be reached until 60 to 90 minutes after ingestion [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">A notable exception is ingestion of nicotine patches, in which nicotine release from the patch matrix can be delayed. Biting, piercing, or chewing a nicotine patch may disrupt the matrix and permit large doses of nicotine to be absorbed if swallowed [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermal</strong> – Green tobacco sickness from occupational or farming exposure may have onset of symptoms as early as 15 minutes after contact with dew-laden tobacco leaves [<a href="#rid29">29</a>], but typically, symptoms begin after several hours (mean 10 hours; range 3 to 17 hours in one report).</p><p></p><p class="bulletIndent1">Dermal absorption from nicotine patches has been demonstrated in vitro [<a href="#rid17">17,30</a>], and cases of toxicity from dermal exposure are reported [<a href="#rid15">15,18</a>]. In children, onset of symptoms after dermal exposure has varied from as short as 15 minutes (nicotine patch mistaken for a bandage and applied to an open wound) to several hours [<a href="#rid15">15</a>]. Severe symptoms including seizures, cardiovascular effects, and respiratory failure have occurred after 1.5 to 24 hours in adults who intentionally serially applied multiple nicotine patches [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H1234979897"><span class="h2">Toxicity by nicotine source</span></p><p class="headingAnchor" id="H1874272854"><span class="h3">E-cigarette (nicotine) solution</span><span class="headingEndMark"> — </span>Although most exposures result in minimal or no toxicity, concentrated nicotine solution used in e-cigarettes can cause major and life-threatening poisoning after ingestion, especially in young children [<a href="#rid1">1,2,5</a>]. E-cigarettes are electronic nicotine delivery systems that vaporize a liquid nicotine solution (also called vape juice, e-liquid, or e-juice) to be inhaled by the user  (<a class="graphic graphic_figure graphicRef98585" href="/d/graphic/98585.html" rel="external">figure 2</a>). Some e-cigarettes use pre-filled cartridges or pods, while others have a refillable reservoir  (<a class="graphic graphic_figure graphicRef126552" href="/d/graphic/126552.html" rel="external">figure 3</a>). These vaping liquids contain varying nicotine concentrations, which typically range from 0.5 to 36 mg/mL, though some pod-based nicotine solutions are much more concentrated. (See  <a class="medical medical_review" href="/d/html/98400.html" rel="external">"Vaping and e-cigarettes", section on 'E-cigarette liquid components'</a>.)</p><p class="headingAnchor" id="H2837949821"><span class="h3">Nicotine- and tobacco-containing products</span><span class="headingEndMark"> — </span>The potential for toxicity from tobacco and nicotine cessation products correlates with the amount or concentration of nicotine; ingestion of &gt;0.1 mg/kg is associated with toxicity [<a href="#rid10">10</a>] (see <a class="local">'Toxic dose'</a> above). Ingestion in children is also encouraged by products with fruit or candy flavoring (snus and orbs) and, for orbs, a candy-like appearance. The table provides nicotine concentration and estimated amount of tobacco or nicotine product that may produce nicotine toxicity  (<a class="graphic graphic_table graphicRef138391" href="/d/graphic/138391.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco products (cigarettes, cigars, chewing tobacco, snuff, and pipe tobacco) – A typical cigarette contains 7 to 15 mg of nicotine [<a href="#rid31">31</a>]. Cigars vary greatly in size and total tobacco content but generally have more nicotine than cigarettes. Chewing tobacco and dipping tobacco (moist snuff) are shredded or pulverized plant material, which may be flavored or sweetened, and are typically buffered to a neutral or slightly alkaline pH to enhance absorption  (<a class="graphic graphic_table graphicRef50718" href="/d/graphic/50718.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/6916.html" rel="external">"Patterns of tobacco use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Smoking cessation products (nicotine gum, snus, and transdermal nicotine patches) – Nicotine gum, often used as an aid to smoking cessation, contains 2 or 4 mg of nicotine [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">Transdermal nicotine patches are formulated to deliver between 5 and 22 mg of nicotine over a 16- to 24-hour period (0.3 to 0.9 mg/hour) [<a href="#rid15">15,33</a>]. The total content within the transdermal nicotine patches varies by manufacturer but can be as high as 118 mg. Up to 74 percent of the total nicotine content may remain in the patch after use . Children who have applied nicotine patches to their skin can develop symptoms, typically if exposed for 20 minutes or longer [<a href="#rid15">15</a>]. Patches have also been misused by adults in self-harm attempts [<a href="#rid18">18</a>], including one reported fatality [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">Ingestion of whole patches has the potential to cause delayed and prolonged toxicity [<a href="#rid15">15</a>]. Patches that are torn or bitten and then ingested can result in more rapid toxicity.</p><p></p><p class="headingAnchor" id="H1472799112"><span class="h3">Tobacco and other nicotinic plants</span><span class="headingEndMark"> — </span>Nicotiana is a genus of plants in the Solanaceae family (the nightshades, many of which produce toxic alkaloids). <em>Nicotiana tabacum</em> is the cultivated tobacco plant used for making cigars, cigarettes, pipe tobacco, and chewing tobacco; but many other species within the genus are popular garden plants. The plants can be recognized by their tubular flowers with five petals. Their leaves tend to be large and dark green, and they may be hairy or sticky to the touch.</p><p>Most plants in the genus contain nicotine or similar alkaloids (such as anabasine, another nicotinic receptor agonist), with <em>nicotiana tabacum</em> containing the greatest content by dry weight. This content can vary from 0.1 to 4.9 percent of dry weight [<a href="#rid35">35</a>]. Most cultivated tobacco plant exposures produce mild or moderate symptoms [<a href="#rid1">1</a>]. However, brewed tobacco plant material produces a concentrated nicotine solution that has been used for self-harm resulting in serious toxicity and death [<a href="#rid7">7,8</a>]. Nicotine toxicity from dermal occupational exposure during farming of tobacco is also described. (See <a class="local">'Green tobacco sickness'</a> below.)</p><p>Exposures to other nicotinic plants are rare, but serious toxicity including death has occurred after exploratory ingestions of <em>Conium maculatum</em> (poison hemlock) by young children or from foragers who mistake poison hemlock for wild carrots or parsnips [<a href="#rid9">9,10</a>]. <em>Baptisia australis</em> has been mistaken for wild asparagus and caused nausea, vomiting, diarrhea, generalized weakness, and ataxia [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1540011770"><span class="h3">Nicotine-containing pesticides</span><span class="headingEndMark"> — </span>Although banned in many countries, including the United States, highly concentrated nicotine pesticides may be available in other parts of the world. These agents are rapidly absorbed, and life-threatening nicotinic poisoning or death after ingestion or dermal exposure has been described [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2226483124"><span class="h2">Neonicotinoids</span><span class="headingEndMark"> — </span>Neonicotinoids are widely used as insecticides and include compounds such as imidacloprid, thiamethoxam, clothianidin, acetamiprid, and thiacloprid. Despite having structural similarities to nicotine, neonicotinoids produce varying patterns of activity at nAChR subtypes [<a href="#rid12">12</a>]. (See <a class="local">'Mechanism of toxicity'</a> above.)</p><p>Compared with concentrated liquid nicotine insecticides, neonicotinoid exposures are less dangerous in overdose. For example, even with large, intentional ingestions of neonicotinoids, most patients develop only mild to moderate symptoms of nausea, vomiting, diarrhea, abdominal pain, and headache that resolve with supportive care. However, life-threatening coma, respiratory failure, and/or hepatotoxicity and death have been described [<a href="#rid37">37,38</a>]. The liver injury reported in individuals who ingested imidacloprid-based insecticides includes cholestatic, hepatocellular, and mixed patterns of injury. It is unclear whether imidacloprid, or one of the other chemical components (eg solvents or surfactants) in these insecticide solutions, is responsible for hepatotoxicity [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H604304514"><span class="h1">CLINICAL FEATURES OF POISONING</span></p><p>Approximately 20 to 33 percent of patients with a nicotine exposure will become symptomatic [<a href="#rid1">1,40</a>]. The classic biphasic appearance, initial stimulation followed by later depression (see <a class="local">'Mechanism of toxicity'</a> above), is not frequently observed in clinical practice.</p><p>Nicotine poisoning can be classified by the severity of signs and symptoms  (<a class="graphic graphic_table graphicRef138390" href="/d/graphic/138390.html" rel="external">table 3</a>) [<a href="#rid5">5,40,41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild</strong> – Clinical findings of mild nicotine poisoning include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nausea and vomiting</p><p class="bulletIndent2"><span class="glyph">•</span>Salivation</p><p class="bulletIndent2"><span class="glyph">•</span>Drowsiness</p><p class="bulletIndent2"><span class="glyph">•</span>Hyperactivity (for infants, fussy but consolable)</p><p class="bulletIndent2"><span class="glyph">•</span>Tachycardia</p><p class="bulletIndent2"><span class="glyph">•</span>Pallor</p><p class="bulletIndent2"><span class="glyph">•</span>Diaphoresis</p><p class="bulletIndent2"><span class="glyph">•</span>Dizziness</p><p></p><p class="bulletIndent1">Patients with mild poisoning may develop one or more of the signs or symptoms above within 30 minutes of ingestion or dermal exposure; findings typically resolve over the subsequent four to six hours. Other than patients who have ingested a transdermal nicotine patch, individuals who will progress to moderate or severe nicotine poisoning will usually do so within one hour of exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate </strong>– The following clinical findings indicate moderate nicotine poisoning:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension</p><p class="bulletIndent2"><span class="glyph">•</span>Bronchorrhea, wheezing, and tachypnea secondary to bronchorrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Repeated vomiting and/or diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Tremors</p><p class="bulletIndent2"><span class="glyph">•</span>Muscle fasciculations</p><p class="bulletIndent2"><span class="glyph">•</span>Ataxia</p><p class="bulletIndent2"><span class="glyph">•</span>Confusion, agitation, lethargy, and/or irritability (for infants, inconsolable crying)</p><p></p><p class="bulletIndent1">Individuals with moderate signs or symptoms of poisoning warrant emergency supportive care and close monitoring because they can rapidly progress to severe manifestations of nicotine toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe</strong> – Severe findings of nicotine poisoning include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bradyarrhythmias and cardiac arrest</p><p class="bulletIndent2"><span class="glyph">•</span>Hypotension</p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory failure (secondary to muscle paralysis)</p><p class="bulletIndent2"><span class="glyph">•</span>Seizures </p><p class="bulletIndent2"><span class="glyph">•</span>Coma</p><p></p><p class="headingAnchor" id="H303275481"><span class="h1">TELEPHONE TRIAGE</span><span class="headingEndMark"> — </span>Patients with the following features of nicotine exposure warrant referral for emergency evaluation and treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic individuals with more than minimal symptoms of nausea or self-limited vomiting (see <a class="local">'Clinical features of poisoning'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High-risk exposures, even if initially asymptomatic, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion or dermal exposure to a concentrated nicotine solution (eg, e-cigarette cartridge or refill)</p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion of a transdermal nicotine patch [<a href="#rid15">15</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion of tobacco or tobacco products with estimated dose &gt;0.1 mg/kg  (<a class="graphic graphic_table graphicRef138391" href="/d/graphic/138391.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic after intentional ingestion</p><p></p><p>The following nicotine exposures may be observed at home with scheduled telephone or video conference follow-up when available:</p><p class="bulletIndent1"><span class="glyph">●</span>Children who ingest:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;1 cigarette or &lt;3 cigarette butts [<a href="#rid42">42,43</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>A single piece of 2 mg gum [<a href="#rid14">14</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>&lt;1 mouthful of snuff</p><p></p><p class="bulletIndent1">The clinician should counsel the caregiver that their child may experience mild symptoms, such as nausea, salivation, or self-limited vomiting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic children who briefly chew or suck on a transdermal nicotine patch or apply it to intact skin for &lt;20 minutes [<a href="#rid15">15</a>]. The clinician should counsel the parent to remove the patch (if not already performed) and wash the skin with soap and water.</p><p></p><p class="headingAnchor" id="H186727501"><span class="h1">EMERGENCY DEPARTMENT EVALUATION</span></p><p class="headingAnchor" id="H24687275"><span class="h2">Initial stabilization</span><span class="headingEndMark"> — </span>Most nicotine exposures result in no or minimal symptoms. However, nicotine poisoning may present with one or more of the following life-threatening conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Cholinergic effects (ie, miosis, bronchorrhea, wheezing, salivation, vomiting, diarrhea)</p><p class="bulletIndent1"><span class="glyph">●</span>Tachy- or bradydysrhythmias</p><p class="bulletIndent1"><span class="glyph">●</span>Shock due to fluid losses and/or cardiotoxicity</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory depression and apnea</p><p class="bulletIndent1"><span class="glyph">●</span>Skeletal muscle fasciculations followed by weakness/paralysis</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Rhabdomyolysis</p><p></p><p>Initial stabilization of nicotine poisoning is provided in the rapid overview  (<a class="graphic graphic_table graphicRef138390" href="/d/graphic/138390.html" rel="external">table 3</a>).</p><p>Key interventions include:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with dermal exposure, donning of protective personal equipment by all providers and rapid skin decontamination (see <a class="local">'Decontamination'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with signs of excess cholinergic stimulation (miosis, bronchorrhea, wheezing, salivation, vomiting, and/or diarrhea), administration of <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> targeted to drying of bronchial secretions and clearing of wheezing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Support airway, breathing, and circulation (see <a class="local">'Moderate to severe poisoning'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administer oxygen</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticipate need for early endotracheal intubation due to bronchorrhea, coma, seizures, and/or skeletal muscle weakness or paralysis; avoid <a class="drug drug_pediatric" data-topicid="12809" href="/d/drug information/12809.html" rel="external">succinylcholine</a> during rapid sequence intubation (may precipitate or produce prolonged paralysis in nicotine-poisoned patients)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain intravenous (IV) access and, for patients who develop cardiotoxicity or shock caused by significant fluid losses due to vomiting, diarrhea, and/or diaphoresis, provide bolus infusions of normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or balanced crystalloid solution (eg, <a class="drug drug_pediatric" data-topicid="108442" href="/d/drug information/108442.html" rel="external">lactated Ringer</a>) and vasoactive infusions as needed for shock (see  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management"</a> and  <a class="medical medical_review" href="/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treat arrhythmias according to Advanced Cardiac Life Support (ACLS)  (<a class="graphic graphic_algorithm graphicRef130748" href="/d/graphic/130748.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef130747" href="/d/graphic/130747.html" rel="external">algorithm 2</a>) and Pediatric Advanced Life Support (PALS)  (<a class="graphic graphic_algorithm graphicRef129941" href="/d/graphic/129941.html" rel="external">algorithm 3</a> and <a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treat seizures initially with benzodiazepines; for patients with persistent seizures, use <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a>, <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproic acid</a>, or <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a>; avoid <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> or <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> (see  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who develop rhabdomyolysis, IV infusion of normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> to maintain urine output of 200 to 300 mL per hour in adults and 4 mL/kg per hour in children (see  <a class="medical medical_review" href="/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Volume administration'</a>)</p><p></p><p class="headingAnchor" id="H827245963"><span class="h2">History</span><span class="headingEndMark"> — </span>The following historical information is essential for determining the significance of nicotine or tobacco product exposure and directing further management:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>What was the exposure?</strong> – Determine the type of nicotine or tobacco product exposure and potential for toxicity. Exposures with the highest potential for serious toxicity include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion of or dermal exposure to concentrated liquid nicotine found in e-cigarette products or insecticides [<a href="#rid2">2,3,5</a>]. (See <a class="local">'E-cigarette (nicotine) solution'</a> above and <a class="local">'Nicotine-containing pesticides'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingested nicotine doses &gt;0.1 mg/kg are potentially toxic; doses &gt;1 mg/kg (60 mg in adults) are potentially lethal  (<a class="graphic graphic_table graphicRef138391" href="/d/graphic/138391.html" rel="external">table 1</a>). (See <a class="local">'Toxic dose'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion of a transdermal nicotine patch may result in delayed toxicity and has the potential to deliver a high nicotine dose (up to 70 percent of the total dose in the patch is present after being discarded) [<a href="#rid15">15</a>]. (See <a class="local">'Nicotine- and tobacco-containing products'</a> above.)</p><p></p><p class="bulletIndent1">Most cultivated tobacco plant exposures produce, at most, mild or moderate symptoms, often after occupational dermal exposure (green tobacco illness). Exploratory ingestions of other nicotine-containing plants by children are rare and typically innocuous. However, deaths of amateur foragers have occurred after consuming poison hemlock (<em>Conium maculatum</em>) roots that were mistaken for wild carrots or parsnips. (See <a class="local">'Nicotine- and tobacco-containing products'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When did it happen?</strong> – Signs and symptoms of nicotine poisoning usually develop soon after exposure (typically within one hour). Important exceptions that may be associated with delayed toxicity include transdermal nicotine patch ingestion and some patients with dermal exposure to wet tobacco (green tobacco sickness). (See <a class="local">'Onset of toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>How did it happen?</strong> – With the exception of exposure to concentrated nicotine solutions, most exploratory exposures in children or unintentional exposures in adults result in minimal or no toxicity [<a href="#rid1">1,13</a>]. By contrast, intentional ingestions (attempts at self-harm) are more likely to involve high doses of nicotine and other toxic substances [<a href="#rid7">7,8,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Are there symptoms of nicotine toxicity?</strong> – Salivation, nausea, vomiting, weakness, confusion, and dizziness are nonspecific symptoms associated with mild nicotine poisoning. Seizures, lethargy, or coma indicate more serious poisoning. (See <a class="local">'Clinical features of poisoning'</a> above.)</p><p></p><p class="headingAnchor" id="H2490975415"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Most patients will have minimal or no findings after nicotine exposure. In patients with nicotine poisoning, physical examination findings may reflect a spectrum of activation and/or inhibition of nicotinic acetylcholine receptors (nAChRs) (see <a class="local">'Mechanism of toxicity'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General</strong> – Altered mental status may arise from central nervous system stimulation (agitation, confusion, or, in infants, irritability) or depression (lethargy or coma).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vital signs</strong> – Sympathetic stimulation produces tachycardia (typically sinus, but tachyarrhythmias are described) and hypertension; parasympathetic stimulation and fluid loses from cholinergic toxicity can cause bradycardia with hypotension.</p><p></p><p class="bulletIndent1">Bronchorrhea and wheezing from cholinergic activation produces tachypnea. Muscle weakness and central nervous system depression can cause respiratory depression and apnea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholinergic findings</strong> – Prominent cholinergic features after nicotine poisoning consist of bronchorrhea, wheezing, salivation, miosis, vomiting, and diarrhea; salivation alone commonly occurs after small oral ingestions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Musculoskeletal system</strong> – Nicotinic stimulation at the neuromuscular junction results in muscle fasciculations initially and can rapidly progress to depolarizing blockade with muscle weakness and then paralysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system</strong> – Central nervous system toxicity may manifest as seizures, lethargy, or coma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin</strong> – Diaphoresis and pallor can be prominent findings.</p><p></p><p class="headingAnchor" id="H20051799"><span class="h2">Ancillary studies</span></p><p class="headingAnchor" id="H3299394205"><span class="h3">Asymptomatic or minimal toxicity</span><span class="headingEndMark"> — </span>In an unintentional nicotine exposure with minimal toxicity or no symptoms, screening labs are generally not indicated.</p><p>In cases of intentional nicotine exposure (ie, attempt at self-harm), the clinician should obtain plasma levels of <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> and salicylate because these patients can have a life-threatening and treatable ingestion. (See  <a class="medical medical_review" href="/d/html/340.html" rel="external">"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation", section on 'General approach and laboratory evaluation'</a> and  <a class="medical medical_review" href="/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1404186616"><span class="h3">Symptomatic</span><span class="headingEndMark"> — </span>Patients with signs or symptoms of serious nicotine toxicity should undergo the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid bedside test for plasma glucose</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial or venous blood gas</p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes </p><p class="bulletIndent1"><span class="glyph">●</span>Blood urea nitrogen and creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with seizures and all pediatric patients, urine screening for drugs of abuse (see  <a class="medical medical_review" href="/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)", section on 'Utility of DOA screening'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>In postmenarcheal females, urine pregnancy test</p><p class="bulletIndent1"><span class="glyph">●</span>Other toxicologic testing as indicated for potential co-ingestants:</p><p class="bulletIndent2"><span class="glyph">•</span>Serum <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a> and <a class="drug drug_pediatric" data-topicid="12829" href="/d/drug information/12829.html" rel="external">aspirin</a> levels in patients with intentional ingestions</p><p class="bulletIndent2"><span class="glyph">•</span>Rapidly available quantitative levels of potentially ingested drugs or toxins  (<a class="graphic graphic_table graphicRef77841" href="/d/graphic/77841.html" rel="external">table 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (ECG)</p><p class="bulletIndent1"><span class="glyph">●</span>Serial measures of serum creatine kinase and urinalysis (for patients with muscle fasciculations, seizures, and/or paralysis to identify the presence of rhabdomyolysis)</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma and red blood cell cholinesterase (for patients with muscle fasciculations, weakness, and/or paralysis and when history of nicotine exposure is not readily apparent to differentiate nicotine poisoning from organophosphate or carbamate poisoning; results are not immediately available) (see <a class="local">'Differential diagnosis'</a> below)</p><p></p><p>Neuroimaging may be indicated for patients with altered mental status if the diagnosis of poisoning is in doubt or there are clinical findings of head trauma or focal neurologic deficit.</p><p class="headingAnchor" id="H3787750033"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Nicotine poisoning is a clinical diagnosis based upon a history of nicotine or tobacco exposure and clinical features including one or more of the following (see <a class="local">'Clinical features of poisoning'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Cholinergic findings (typically nausea, vomiting, miosis, salivation, bronchorrhea, and/or wheezing)</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system stimulation (confusion, agitation, or, in infants, irritability) or depression (lethargy or coma)</p><p class="bulletIndent1"><span class="glyph">●</span>Tachy- or bradydysrhythmias</p><p class="bulletIndent1"><span class="glyph">●</span>Shock</p><p class="bulletIndent1"><span class="glyph">●</span>Seizures</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle fasciculations</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle weakness or paralysis</p><p></p><p>Urine cotinine and whole blood or plasma nicotine concentrations can be obtained to confirm exposure [<a href="#rid44">44,45</a>] but are not readily available at most health care centers to provide rapid diagnosis during acute treatment. Cotinine is one of the primary metabolites of nicotine and has a much longer half-life (T 13 to 19 hours) than its parent compound, making it the typical biomarker of exposure [<a href="#rid46">46</a>]. However, low levels of urine cotinine may be detectable as a result of passive inhalation (secondhand smoke) [<a href="#rid6">6,47</a>], and, in cases of nicotine poisoning, plasma nicotine or cotinine levels may not correlate with degree of toxicity [<a href="#rid5">5,18</a>]. Considering these factors, qualitative cotinine assays may not be useful in diagnosing nicotine toxicity, though markedly elevated concentrations of cotinine may be indicative of an acute exposure in a child.</p><p class="headingAnchor" id="H3441162890"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In the absence of a clear nicotine exposure history, many of the symptoms of nicotine poisoning are nonspecific and could be confused for other conditions. Additionally, because nicotine poisoning can occur from small quantities, an exposure history may not be immediately apparent.</p><p>The differential diagnosis for patients with suspected nicotine poisoning includes toxic causes of cholinergic effects, vomiting, and altered mental status:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholinergic effects</strong> – The differential diagnosis of toxins causing signs of cholinergic excess (eg, miosis, vomiting, diarrhea, salivation, tachycardia, and/or seizures) is limited:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Organophosphates or carbamates</strong> – Organophosphate or carbamate poisoning is the major toxic exposure, other than nicotine, that presents with cholinergic effects. Organophosphate poisoning may be difficult to differentiate from nicotine poisoning because either toxin can cause cholinergic effects and/or muscle fasciculations followed by paralysis [<a href="#rid48">48</a>]. Low cholinesterase activity level as measured by decreased plasma and/or red blood cell cholinesterase levels indicates organophosphate poisoning (see  <a class="medical medical_review" href="/d/html/339.html" rel="external">"Organophosphate and carbamate poisoning", section on 'Laboratory abnormalities'</a>). However, results of these studies are typically not rapidly available, and interpretation of cholinesterase levels can be difficult due to variation in enzyme activity among patients and day-to-day variations within the same patient. Unlike organophosphates, nicotine does not bind to cholinesterase and should not impact enzyme activity.</p><p></p><p class="bulletIndent2">Because cholinesterase levels are not rapidly available, a trial dose of <a class="drug drug_pediatric" data-topicid="12720" href="/d/drug information/12720.html" rel="external">pralidoxime</a> for patients who develop cholinergic findings or neuromuscular dysfunction may be appropriate. If given, <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> should also be administered concurrently. While pralidoxime may reverse neuromuscular signs of organophosphate poisoning, it does not treat nicotine poisoning. Additional details regarding indications and proper administration of pralidoxime are provided separately. (See  <a class="medical medical_review" href="/d/html/339.html" rel="external">"Organophosphate and carbamate poisoning", section on 'Pralidoxime'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Muscarinic mushrooms</strong> – Although rare, ingestion of muscarinic mushrooms (eg, <em>Clitocybe dealbata</em>, <em>Clitocybe illudens</em>, <em>Inocybe fastigiata</em>, or <em>Boletus calopus</em>) can also cause cholinergic effects, but unlike nicotine exposures, seizures or neuromuscular dysfunction do not occur. Cholinergic mushroom ingestion is typically short lived and not life threatening. A recent history of wild mushroom ingestion can help distinguish this poisoning from mild nicotine poisoning. (See  <a class="medical medical_review" href="/d/html/16135.html" rel="external">"Clinical manifestations and evaluation of mushroom poisoning", section on 'Cholinergic poisoning'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vomiting</strong> – Vomiting is one of the earliest signs of nicotine toxicity. Other agents that can cause vomiting after toxic exposure include iron, salicylates, <a class="drug drug_pediatric" data-topicid="12831" href="/d/drug information/12831.html" rel="external">theophylline</a>, caustic agents, toxic alcohols, arsenic and mercurial salts, nonsteroidal antiinflammatory drugs (NSAIDs), plants, mushrooms, and <a class="drug drug_pediatric" data-topicid="13179" href="/d/drug information/13179.html" rel="external">colchicine</a> [<a href="#rid49">49</a>]. In many instances, the history helps to distinguish nicotine from these toxins. Clinical and/or laboratory findings help to distinguish the following selected poisons from nicotine:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Arsenic</strong> – Elevated spot urine arsenic level (acute poisoning) in patients with garlic odor on the breath, vomiting, diarrhea, and prolonged QTc and/or torsade de pointes on ECG after acute arsenic poisoning. (See  <a class="medical medical_review" href="/d/html/2778.html" rel="external">"Arsenic exposure and chronic poisoning"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13179" href="/d/drug information/13179.html" rel="external">Colchicine</a> – History of colchicine ingestion (medication or plant) associated with onset of multisystem organ failure. (See  <a class="medical medical_review" href="/d/html/6507.html" rel="external">"Potentially toxic plant ingestions in children: Clinical manifestations and evaluation", section on 'Gastroenteritis with systemic toxicity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Iron</strong> – Elevated serum iron level in patients with vomiting (may be hemorrhagic), abdominal pain, and an elevated anion gap metabolic acidosis. (See  <a class="medical medical_review" href="/d/html/6498.html" rel="external">"Acute iron poisoning"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mercury salts</strong> – Elevated whole blood mercury in patients with hemorrhagic gastroenteritis, shock, and acute kidney injury due to acute tubular necrosis. (See  <a class="medical medical_review" href="/d/html/7179.html" rel="external">"Mercury toxicity", section on 'Inorganic mercury salts toxicity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Methylxanthines (caffeine or </strong><a class="drug drug_pediatric" data-topicid="12831" href="/d/drug information/12831.html" rel="external">theophylline</a><strong>)</strong> – Elevated caffeine or theophylline level, especially when associated with seizures and tachyarrhythmias. (See  <a class="medical medical_review" href="/d/html/6501.html" rel="external">"Theophylline poisoning"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mushrooms</strong> – History of mushroom ingestion with vomiting followed by characteristic mushroom syndrome  (<a class="graphic graphic_table graphicRef77875" href="/d/graphic/77875.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/16135.html" rel="external">"Clinical manifestations and evaluation of mushroom poisoning"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NSAIDS</strong> – Serious toxicity occurring only after very large ingestions and consisting of anion gap metabolic acidosis, depressed mental status, and cardiac arrhythmia. (See  <a class="medical medical_review" href="/d/html/341.html" rel="external">"Nonsteroidal antiinflammatory drug (NSAID) poisoning"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Plants</strong> – Plants that contain nicotine or nicotine-like substances that can cause nicotine poisoning are described above (see <a class="local">'Tobacco and other nicotinic plants'</a> above). Many other plants can cause self-limited nausea, vomiting, and diarrhea after ingestion, which either require no therapy or respond to supportive measures  (<a class="graphic graphic_table graphicRef52103" href="/d/graphic/52103.html" rel="external">table 6</a>). More severe gastroenteritis and major toxicity can occur after ingestion of pokeweed (<em>Phytolacca americana</em>), castor bean (<em>Ricinus communis</em>), jequirity bean (<em>Abrus precatorius</em>), and May apple (<a class="drug drug_general" data-topicid="9786" href="/d/drug information/9786.html" rel="external">Podophyllum</a> peltatum)  (<a class="graphic graphic_table graphicRef69016" href="/d/graphic/69016.html" rel="external">table 7</a>). In addition to history, lack of development of other signs of potential cholinergic effects and absence of neuromuscular dysfunction helps to differentiate plant ingestions from nicotine poisoning. (See  <a class="medical medical_review" href="/d/html/6507.html" rel="external">"Potentially toxic plant ingestions in children: Clinical manifestations and evaluation", section on 'Gastrointestinal toxicity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Salicylates</strong> – Elevated anion gap and serum salicylate concentration, especially when associated with hyperthermia and hyperventilation. (See  <a class="medical medical_review" href="/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Toxic alcohols (isopropyl alcohol, methanol, or ethylene glycol)</strong> – Elevated serum osmolal gap (soon after ingestion), anion gap acidosis (several hours after ingestion) associated with vomiting (which may be hemorrhagic), inebriation, and/or coma. (See  <a class="medical medical_review" href="/d/html/334.html" rel="external">"Isopropyl alcohol poisoning"</a> and  <a class="medical medical_review" href="/d/html/336.html" rel="external">"Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">The general approach to vomiting in children and adults is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5902.html" rel="external">"Approach to the infant or child with nausea and vomiting"</a> and  <a class="medical medical_review" href="/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Depressed mental status</strong> – The differential diagnosis and evaluation of lethargy and coma is broad  (<a class="graphic graphic_table graphicRef65571" href="/d/graphic/65571.html" rel="external">table 8</a>). Hypoglycemia is a life-threatening condition that should be assessed with a rapid blood glucose in all patients with depressed mental status. Most organic causes, such as infection or metabolic derangement, would be expected to develop over hours or days, while toxic ingestions typically manifest rapidly. The evaluation of stupor and coma, including initial emergency stabilization and treatment, is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6225.html" rel="external">"Evaluation of stupor and coma in children"</a> and  <a class="medical medical_review" href="/d/html/5104.html" rel="external">"Stupor and coma in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizures</strong> – Except for organophosphate or carbamate poisoning, nicotine poisoning differs from most toxic and other conditions that cause seizures because of the presence of cholinergic effects and/or skeletal muscle fasciculations and paralysis. Acute onset of seizures and seizure-like movements are a common, important feature of many other poisonings and medical conditions including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypoglycemia (see  <a class="medical medical_review" href="/d/html/1798.html" rel="external">"Hypoglycemia in adults without diabetes mellitus: Determining the etiology"</a> and  <a class="medical medical_review" href="/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sympathomimetic overdose (see  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication"</a> and  <a class="medical medical_review" href="/d/html/82952.html" rel="external">"Acute amphetamine and synthetic cathinone ("bath salt") intoxication"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticholinergic poisoning (see  <a class="medical medical_review" href="/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serotonin syndrome (see  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Phencyclidine intoxication (see  <a class="medical medical_review" href="/d/html/313.html" rel="external">"Phencyclidine (PCP) intoxication in adults"</a> and  <a class="medical medical_review" href="/d/html/6506.html" rel="external">"Phencyclidine (PCP) intoxication in children and adolescents"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13393" href="/d/drug information/13393.html" rel="external">Isoniazid</a> poisoning (see  <a class="medical medical_review" href="/d/html/316.html" rel="external">"Isoniazid (INH) poisoning"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12551" href="/d/drug information/12551.html" rel="external">Lidocaine</a> toxicity (see  <a class="medical medical_review" href="/d/html/90613.html" rel="external">"Local anesthetic systemic toxicity"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Strychnine poisoning (see  <a class="medical medical_review" href="/d/html/310.html" rel="external">"Strychnine poisoning"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Meningitis (see  <a class="medical medical_review" href="/d/html/5983.html" rel="external">"Viral meningitis in children: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1296.html" rel="external">"Aseptic meningitis in adults"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Encephalitis (see  <a class="medical medical_review" href="/d/html/1284.html" rel="external">"Viral encephalitis in adults"</a> and  <a class="medical medical_review" href="/d/html/6042.html" rel="external">"Acute viral encephalitis in children: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tetanus (see  <a class="medical medical_review" href="/d/html/5525.html" rel="external">"Tetanus"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intracranial hemorrhage (see  <a class="medical medical_review" href="/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6610.html" rel="external">"Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children"</a> and  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1105.html" rel="external">"Subdural hematoma in adults: Etiology, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stroke (see  <a class="medical medical_review" href="/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke"</a> and  <a class="medical medical_review" href="/d/html/6214.html" rel="external">"Ischemic stroke in children: Clinical presentation, evaluation, and diagnosis"</a>)</p><p></p><p class="bulletIndent2">The evaluation of new-onset seizures is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a> and  <a class="medical medical_review" href="/d/html/6218.html" rel="external">"Seizures and epilepsy in children: Clinical and laboratory diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H722416009"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1864013991"><span class="h2">Decontamination</span><span class="headingEndMark"> — </span>The approach to decontamination of patients with nicotine exposure is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Personal protective equipment</strong> – For patients who ingest nicotine, no special personal protective equipment is required.</p><p></p><p class="bulletIndent1">For dermal exposures with concentrated nicotine products or industrial, agricultural, or insecticide exposures, providers should wear a waterproof gown, gloves, and eye protection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>External decontamination of dermal exposure</strong> – All patients with possible dermal exposure to nicotine should undergo careful skin inspection and removal of any transdermal nicotine patches. In addition, check the vagina, rectum, and roof of the mouth.</p><p></p><p class="bulletIndent1">Patients with dermal exposure to concentrated liquid nicotine (eg, spilled e-cigarette liquid, nicotinic pesticides) or damp plant material (as in green tobacco sickness) should undergo external decontamination by health care providers in personal protective equipment as follows [<a href="#rid41">41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Remove all clothing (at least down to their undergarments) and place in a labeled, waterproof, and durable 6-mil polyethylene or similar bag</p><p class="bulletIndent2"><span class="glyph">•</span>Avoid breaking the patient's skin during the decontamination process; cover all open wounds</p><p class="bulletIndent2"><span class="glyph">•</span>Starting at the head and working down to the feet, thoroughly wash and rinse the contaminated skin of the patient using soap and, preferably, warm water at low pressure</p><p class="bulletIndent2"><span class="glyph">•</span>Gently pat the patient dry and cover with clean, dry linen or other appropriate barrier to prevent hypothermia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal decontamination</strong> — Although evidence of clinical benefit in patients who ingest nicotine or tobacco products is lacking, activated charcoal can effectively bind to and reduce absorption of nicotine. For patients who present within one hour of a potentially toxic ingestion of nicotine or a tobacco product or within three hours of ingestion of a transdermal nicotine patch, we suggest administration of activated charcoal (dose: 1 g/kg up to 50 g; activated charcoal without <a class="drug drug_pediatric" data-topicid="12801" href="/d/drug information/12801.html" rel="external">sorbitol</a> preferred in pediatric patients) (see  <a class="medical medical_review" href="/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>). Vomiting may prevent administration of activated charcoal.</p><p></p><p class="bulletIndent1">Activated charcoal should not be given to patients with depressed mental status unless the airway is first secured. It is also contraindicated if there has been co-ingestion of a caustic substance or a hydrocarbon.</p><p></p><p class="bulletIndent1">For patients who present within one hour after a large ingestion of a concentrated liquid nicotine product, nasogastric aspiration and lavage with normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> may be attempted, but benefit of this approach is not established. Whenever possible, this decision should be made in consultation with a medical toxicologist. For patients who cannot protect their airway, endotracheal intubation should be performed before nasogastric aspiration. Otherwise, gastric lavage is generally not recommended for patients with nicotine, tobacco, or tobacco product ingestion because the potential risks of the procedure likely outweigh the benefit, considering that most nicotine exposures can be managed supportively.</p><p></p><p class="headingAnchor" id="H1341889307"><span class="h2">Moderate to severe poisoning</span><span class="headingEndMark"> — </span>There is no specific antidote for nicotine poisoning. Excellent supportive care, directed at clinical findings, is the mainstay of treatment as provided in the rapid overview  (<a class="graphic graphic_table graphicRef138390" href="/d/graphic/138390.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H1226797279"><span class="h3">Cholinergic signs and symptoms</span><span class="headingEndMark"> — </span>Cholinergic signs and symptoms (eg, bronchorrhea, wheezing, bradycardia, salivation, miosis, vomiting, and/or diarrhea) are treated as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">Atropine</a> – Intramuscular (IM) or intravenous (IV) atropine (0.01 to 0.02 mg/kg, maximum single dose 1 to 2 mg); atropine dosing should be repeated every three to five minutes as needed until drying of respiratory secretions has occurred. Tachycardia is not a contraindication to atropine because respiratory secretions may contribute to respiratory failure; tachycardia is typically well-tolerated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13389" href="/d/drug information/13389.html" rel="external">Ipratropium</a><strong> bromide</strong> – For patients with wheezing, inhaled ipratropium bromide (500 mcg) may be administered with <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> and may be repeated every 15 minutes for a total of three doses in patients with persistent wheezing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiemetics</strong> – Relative to other antiemetics, <a class="drug drug_pediatric" data-topicid="12659" href="/d/drug information/12659.html" rel="external">ondansetron</a> has a low risk for dystonia or other neurologic side effects and may be used to treat either isolated vomiting or vomiting in association with other cholinergic findings.</p><p></p><p class="headingAnchor" id="H3304715299"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>Initial treatment of generalized seizures caused by nicotine poisoning consists of:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benzodiazepines</strong> – Benzodiazepines such as IV <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a> or <a class="drug drug_pediatric" data-topicid="13223" href="/d/drug information/13223.html" rel="external">diazepam</a> are the first-line therapy for all patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-line antiseizure medications</strong> – If seizures persist despite repeated doses of benzodiazepines, <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a> is typically recommended as a second-line agent in patients with toxin-induced seizures; <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> or <a class="drug drug_pediatric" data-topicid="13327" href="/d/drug information/13327.html" rel="external">fosphenytoin</a> should be avoided because they are typically less effective or (for certain agents such as cocaine, <a class="drug drug_pediatric" data-topicid="12554" href="/d/drug information/12554.html" rel="external">lindane</a>, or <a class="drug drug_pediatric" data-topicid="12831" href="/d/drug information/12831.html" rel="external">theophylline</a>) may intensify seizures (see  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'Fosphenytoin and phenytoin'</a>). Evidence for the use of <a class="drug drug_pediatric" data-topicid="12910" href="/d/drug information/12910.html" rel="external">levetiracetam</a> or <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproic acid</a> for toxin-induced seizures is lacking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory convulsive status epilepticus</strong> – For refractory convulsive status epilepticus, treatment consists of a continuous infusion of:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">Midazolam</a> (preferred for adults and children)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12741" href="/d/drug information/12741.html" rel="external">Propofol</a> (older adolescents and adults only, avoid in children) </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12693" href="/d/drug information/12693.html" rel="external">Pentobarbital</a> (adults and children)</p><p></p><p class="bulletIndent1">Patients with refractory convulsive status epilepticus warrant continuous electroencephalogram (EEG) to monitor for continued seizure activity. Drug dosing is provided in the algorithms for adults  (<a class="graphic graphic_algorithm graphicRef74649" href="/d/graphic/74649.html" rel="external">algorithm 5</a>) and children  (<a class="graphic graphic_algorithm graphicRef131955" href="/d/graphic/131955.html" rel="external">algorithm 6</a>) and provided separately. (See  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children", section on 'Emergency antiseizure treatment'</a> and  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'Emergency antiseizure treatment'</a>.)</p><p></p><p class="headingAnchor" id="H710233251"><span class="h3">Lethargy or coma</span><span class="headingEndMark"> — </span>Lethargy or coma may be seen as a primary sign of nicotine poisoning or become established after an initial presentation marked by agitation or seizures. Patients with lethargy or coma should have close monitoring of oxygenation and ventilation. Endotracheal intubation by rapid sequence intubation and mechanical ventilation are indicated for patients who appear unable to protect their airway or develop hypercarbia or hypoxia. (See  <a class="medical medical_review" href="/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach"</a> and  <a class="medical medical_review" href="/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a>.)</p><p>During rapid sequence intubation, non-depolarizing agents such as <a class="drug drug_pediatric" data-topicid="12774" href="/d/drug information/12774.html" rel="external">rocuronium</a> should be used, and <a class="drug drug_pediatric" data-topicid="12809" href="/d/drug information/12809.html" rel="external">succinylcholine</a>, which also has direct effect on the neuromuscular junction and may precipitate or prolong toxin-induced paralysis, should be <strong>avoided</strong>. Mechanical ventilation may be complicated by bronchorrhea and bronchospasm; initial ventilation settings similar to those used for patients with status asthmaticus are advised. (See  <a class="medical medical_review" href="/d/html/97585.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Endotracheal intubation and mechanical ventilation", section on 'Endotracheal intubation and mechanical ventilation'</a> and  <a class="medical medical_review" href="/d/html/570.html" rel="external">"Invasive mechanical ventilation in adults with acute exacerbations of asthma"</a>.)</p><p class="headingAnchor" id="H3623936893"><span class="h3">Muscle fasciculations and paralysis</span><span class="headingEndMark"> — </span>Muscle fasciculations indicate activation of the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction and signal a high risk for progression to generalized skeletal muscle weakness and paralysis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endotracheal intubation and mechanical ventilation</strong> – The clinician should anticipate the need for endotracheal intubation and mechanical ventilation as indicated by rising end-tidal carbon dioxide (EtCO<sub>2</sub>), hypercarbia on blood gases, or significant hypoxia.</p><p></p><p class="bulletIndent1">For patients with nicotine-induced paralysis, lower-than-normal doses (ie, half-dose) of muscle relaxants may permit safe intubating conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presumptive administration of </strong><a class="drug drug_pediatric" data-topicid="12720" href="/d/drug information/12720.html" rel="external">pralidoxime</a> – For patients with neuromuscular effects following an exposure poisoning but uncertainty as to the specific toxic agent, presumptive administration of pralidoxime for possible organophosphate poisoning is a reasonable approach, especially in regions where organophosphates are widely used [<a href="#rid38">38</a>]. Pralidoxime may benefit patients with organophosphate poisoning but is ineffective for nicotine poisoning. If pralidoxime is given, <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> should also be administered concurrently.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12720" href="/d/drug information/12720.html" rel="external">Pralidoxime</a> dosing and administration is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/339.html" rel="external">"Organophosphate and carbamate poisoning", section on 'Pralidoxime'</a>.)</p><p></p><p class="headingAnchor" id="H3204577586"><span class="h3">Shock</span><span class="headingEndMark"> — </span>Shock with or without hypotension after nicotine poisoning may arise from fluid losses, bradyarrhythmias, and/or myocardial depression. Treatment includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of bradycardia (see discussion of cardiac arrhythmias below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid infusion of IV isotonic crystalloid (eg, normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or balanced crystalloid solutions [eg, <a class="drug drug_pediatric" data-topicid="108442" href="/d/drug information/108442.html" rel="external">lactated Ringer</a>]). The volume and rate depend upon the degree of shock and whether pre-existing conditions (eg, heart failure) are present. (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management", section on 'Fluid resuscitation'</a> and  <a class="medical medical_review" href="/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'Intravenous fluids'</a>.)</p><p></p><p>If hypotensive shock persists despite fluid administration, give vasoactive agents such as <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a> (patients with high heart rate) or <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a> (patients with relative bradycardia).<strong> </strong></p><p class="headingAnchor" id="H2236892276"><span class="h3">Cardiac arrhythmias</span><span class="headingEndMark"> — </span>Sinus tachycardia is the most common arrhythmia after nicotine poisoning. It does not typically require specific treatment although it may indicate hypovolemia caused by vomiting and diarrhea.</p><p><a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">Atropine</a> as described above is the primary treatment for bradycardia with poor perfusion after nicotine poisoning. If persistent, the clinician should provide further treatment according to Advanced Cardiac Life Support (ACLS)  (<a class="graphic graphic_algorithm graphicRef130748" href="/d/graphic/130748.html" rel="external">algorithm 1</a>) or Pediatric Advanced Life Support (PALS)  (<a class="graphic graphic_algorithm graphicRef129941" href="/d/graphic/129941.html" rel="external">algorithm 3</a>) guidelines.</p><p>Tachyarrhythmias (eg, supraventricular tachycardia or ventricular tachycardia) may occur due to sympathetic stimulation during nicotine poisoning and should be managed according to ACLS  (<a class="graphic graphic_algorithm graphicRef130747" href="/d/graphic/130747.html" rel="external">algorithm 2</a>) or PALS guidelines  (<a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 4</a>).</p><p class="headingAnchor" id="H8272849"><span class="h3">Rhabdomyolysis</span><span class="headingEndMark"> — </span>Patients with rhabdomyolysis should receive IV isotonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> titrated to produce a urine output of 200 to 300 mL/hour in adults (4 mL/kg per hour in children). The suggested initial fluid volume and rate in adults is 1 to 2 L/hour (20 to 40 mL/kg per hour in children). (See  <a class="medical medical_review" href="/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>.)</p><p class="headingAnchor" id="H1147479247"><span class="h2">Mild poisoning or asymptomatic</span><span class="headingEndMark"> — </span>Asymptomatic patients and those with signs of mild poisoning should undergo decontamination (see <a class="local">'Decontamination'</a> above) as needed and undergo careful monitoring for progression of toxicity for four to six hours following exposure to liquids, plant material, or cigarettes/cigars. patients who are asymptomatic after six hours of observation may be discharged home or, for patients who intended self-harm, cleared for mental health evaluation.</p><p>If a nicotine patch is ingested, observation for 24 hours is warranted because toxicity may be delayed.</p><p class="headingAnchor" id="H2376959912"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>As with prevention of other poisonings, public awareness campaigns and child-resistant packaging may reduce exposures to nicotine-containing products and substances. For example, in an observational study of e-cigarette and liquid nicotine exposures in the United States, institution of child-resistant packaging laws was associated with a significant decrease in reported exposures [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3714062157"><span class="h1">GREEN TOBACCO SICKNESS</span><span class="headingEndMark"> — </span>Green tobacco sickness refers to nicotine toxicity caused by dermal absorption from tobacco leaves in field workers during harvest [<a href="#rid50">50</a>]. Factors associated with green tobacco sickness include:</p><p class="bulletIndent1"><span class="glyph">●</span>Working in tobacco fields when the crop is wet (eg, early morning dew, during or shortly after a rainstorm, or days with high ambient humidity) [<a href="#rid50">50,51</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsmoking workers (due to lower tolerance to nicotine when compared with smokers) [<a href="#rid50">50</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Younger age, with children and adolescents at highest risk [<a href="#rid51">51</a>]</p><p></p><p class="headingAnchor" id="H2132125693"><span class="h2">Clinical manifestations and diagnosis</span><span class="headingEndMark"> — </span>Green tobacco sickness may have rapid onset while the worker is in the field or can be delayed for several hours [<a href="#rid50">50</a>]. Typical clinical findings consist of pallor, nausea, vomiting, lightheadedness, and headache [<a href="#rid19">19,20,52</a>]. Less commonly, diaphoresis, salivation, copious bronchial secretions, diarrhea, muscle weakness, and fluctuations in heart rate and blood pressure may occur [<a href="#rid50">50,51</a>]. Rarely, seizures have been described [<a href="#rid51">51,53</a>]. Green tobacco sickness typically resolves within three days.</p><p class="bulletIndent1">The diagnosis of green tobacco sickness is based upon a history of tobacco leaf exposure and clinical findings. If the diagnosis is in doubt, elevated blood, urine, or salivary cotinine levels can confirm the diagnosis in nonsmokers and smokers with mild to moderate use [<a href="#rid50">50,54</a>]. However, toxic cotinine levels have not been well established in heavy tobacco users.</p><p></p><p class="headingAnchor" id="H2448888382"><span class="h2">Management</span><span class="headingEndMark"> — </span>In most patients, treatment requires prevention of further exposure and supportive care as follows [<a href="#rid50">50</a>]:</p><p class="bulletIndent2"><span class="glyph">•</span>Remove the worker from the field</p><p class="bulletIndent2"><span class="glyph">•</span>Have the worker shower and change clothing</p><p class="bulletIndent2"><span class="glyph">•</span>Encourage adequate hydration and rest</p><p class="bulletIndent2"><span class="glyph">•</span>Give antiemetics (eg, <a class="drug drug_pediatric" data-topicid="12659" href="/d/drug information/12659.html" rel="external">ondansetron</a>) and intravenous (IV) fluids to patients with persistent vomiting but no other muscarinic signs (eg, bronchorrhea, salivation, or wheezing)</p><p class="bulletIndent2"><span class="glyph">•</span>Prevent the worker from returning to the tobacco field until all signs and symptoms have resolved</p><p></p><p>Management of more serious nicotine poisoning caused by green tobacco sickness is as for moderate to severe nicotine poisoning. (See <a class="local">'Management'</a> above.)</p><p class="headingAnchor" id="H521052534"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112688.html" rel="external">"Society guideline links: Poisoning prevention"</a>.)</p><p class="headingAnchor" id="H4025880974"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and toxicity</strong> – Most nicotine exposures arise from exploratory ingestions in children and result in no effect or minimal symptoms. However, severe toxicity can occur. High-risk exposures include (see <a class="local">'Epidemiology'</a> above and <a class="local">'Toxicity by nicotine source'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion or dermal exposure to a concentrated nicotine solution (eg, e-cigarette cartridge or refill)</p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion of a transdermal nicotine patch </p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion of tobacco or tobacco products with estimated dose &gt;0.1 mg/kg  (<a class="graphic graphic_table graphicRef138391" href="/d/graphic/138391.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Onset of toxicity</strong> – Signs and symptoms of nicotine poisoning usually develop soon after exposure (typically within one hour). Important exposures associated with delayed toxicity include transdermal nicotine patch ingestion, cutaneous patch application, or dermal exposure to wet tobacco plants (green tobacco sickness). (See <a class="local">'Onset of toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features and diagnosis</strong> – Nicotine poisoning is a clinical diagnosis based upon a history of nicotine or tobacco exposure. Salivation, nausea, vomiting, weakness, confusion, and dizziness are nonspecific symptoms associated with mild nicotine poisoning. Clinical features of severe poisoning include (see <a class="local">'Clinical features of poisoning'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cholinergic findings (typically nausea, vomiting, miosis, salivation, bronchorrhea, and/or wheezing)</p><p class="bulletIndent2"><span class="glyph">•</span>Central nervous system stimulation (confusion, agitation, or, in infants, irritability) or depression (lethargy or coma)</p><p class="bulletIndent2"><span class="glyph">•</span>Tachy- or bradydysrhythmias</p><p class="bulletIndent2"><span class="glyph">•</span>Shock</p><p class="bulletIndent2"><span class="glyph">•</span>Seizures</p><p class="bulletIndent2"><span class="glyph">•</span>Muscle fasciculations</p><p class="bulletIndent2"><span class="glyph">•</span>Muscle weakness or paralysis</p><p></p><p class="bulletIndent1">Definitive laboratory testing is not available in a timely fashion but may be indicated to confirm exposure (obtain blood and urine samples for cotinine and other nicotine metabolites).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapid overview</strong> – A summary table provides guidance for the emergency evaluation and management of patients with nicotine poisoning  (<a class="graphic graphic_table graphicRef138390" href="/d/graphic/138390.html" rel="external">table 3</a>). Management is based upon the type of exposure and anticipated toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decontamination</strong> – Carefully inspect the skin, vagina, rectum, and roof of the mouth and remove any transdermal nicotine patches. Patients with dermal exposure to concentrated liquid nicotine (eg, spilled e-cigarette liquid, nicotinic pesticides) or damp plant material (as in green tobacco sickness) should undergo external decontamination by health care providers in personal protective equipment. (See <a class="local">'Decontamination'</a> above.)</p><p></p><p class="bulletIndent1">For patients who present within one hour of a potentially toxic ingestion of nicotine or a tobacco product or within three hours of ingestion of a transdermal nicotine patch, we suggest administration of activated charcoal without <a class="drug drug_pediatric" data-topicid="12801" href="/d/drug information/12801.html" rel="external">sorbitol</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe poisoning</strong> – There is no antidote for nicotine poisoning. For moderate to severe nicotine poisoning, treatment is supportive based upon physical findings (see <a class="local">'Initial stabilization'</a> above and <a class="local">'Moderate to severe poisoning'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cholinergic toxicity (miosis, bronchorrhea, wheezing, salivation, vomiting, and/or diarrhea)</strong> – Key interventions include administration of <a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a> targeted to drying of bronchial secretions and clearing of wheezing, inhaled <a class="drug drug_pediatric" data-topicid="13389" href="/d/drug information/13389.html" rel="external">ipratropium</a> bromide for wheezing, and <a class="drug drug_pediatric" data-topicid="12659" href="/d/drug information/12659.html" rel="external">ondansetron</a> for vomiting. (See <a class="local">'Cholinergic signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bronchorrhea unresponsive to </strong><a class="drug drug_pediatric" data-topicid="12875" href="/d/drug information/12875.html" rel="external">atropine</a><strong> therapy, coma, seizures, and/or skeletal muscle weakness or paralysis</strong> – Perform timely endotracheal intubation; avoid <a class="drug drug_pediatric" data-topicid="12809" href="/d/drug information/12809.html" rel="external">succinylcholine</a> during rapid sequence intubation (may precipitate or produce prolonged paralysis). For patients with fasciculations, muscle weakness, or paralysis but uncertainty as to the specific toxic agent, presumptive administration of <a class="drug drug_pediatric" data-topicid="12720" href="/d/drug information/12720.html" rel="external">pralidoxime</a> for possible organophosphate poisoning is a reasonable approach, especially in regions where organophosphates are widely used. Pralidoxime is ineffective for paralysis caused by nicotine. (See <a class="local">'Muscle fasciculations and paralysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Shock from vomiting, diarrhea, diaphoresis, and/or myocardial depression</strong> – Provide rapid infusion of isotonic <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> or balanced crystalloid solutions according to the degree of shock and presence of pre-existing conditions (eg, heart failure). Vasoactive infusions of <a class="drug drug_pediatric" data-topicid="12650" href="/d/drug information/12650.html" rel="external">norepinephrine</a>, <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>, or <a class="drug drug_pediatric" data-topicid="13248" href="/d/drug information/13248.html" rel="external">dopamine</a> are warranted for fluid refractory shock. (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management"</a> and  <a class="medical medical_review" href="/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bradyarrhythmias or tachyarrhythmias</strong> – Provide resuscitation according to Advanced Cardiac Life Support (ACLS)  (<a class="graphic graphic_algorithm graphicRef130748" href="/d/graphic/130748.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef130747" href="/d/graphic/130747.html" rel="external">algorithm 2</a>) and Pediatric Advanced Life Support (PALS)  (<a class="graphic graphic_algorithm graphicRef129941" href="/d/graphic/129941.html" rel="external">algorithm 3</a> and <a class="graphic graphic_algorithm graphicRef129940" href="/d/graphic/129940.html" rel="external">algorithm 4</a>) guidelines.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Status epilepticus</strong> – First-line therapy is a benzodiazepine (eg, <a class="drug drug_pediatric" data-topicid="12565" href="/d/drug information/12565.html" rel="external">lorazepam</a>), if additional antiseizure medication is needed, <a class="drug drug_pediatric" data-topicid="12698" href="/d/drug information/12698.html" rel="external">phenobarbital</a> is preferred. For refractory convulsive status epilepticus, <a class="drug drug_pediatric" data-topicid="12611" href="/d/drug information/12611.html" rel="external">midazolam</a> infusion is preferred. (See <a class="local">'Seizures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rhabdomyolysis</strong> – Provide an intravenous (IV) infusion of normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> to maintain urine output of 200 to 300 mL per hour in adults and 4 mL/kg per hour in children and urinary alkalinization. (See  <a class="medical medical_review" href="/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)", section on 'Volume administration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic exposure or mild poisoning</strong> – Asymptomatic patients and those with mild poisoning after ingestion of nicotine or a tobacco product can rapidly progress to moderate or severe poisoning and require close monitoring. Patients who ingest a transdermal patch require observation for 24 hours because toxicity may be delayed; otherwise, patients who are asymptomatic after six hours of observation may be discharged home or, for patients who intended self-harm, cleared for mental health evaluation.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila) 2021; 59:1282.</a></li><li><a class="nounderline abstract_t">Solarino B, Rosenbaum F, Riesselmann B, et al. Death due to ingestion of nicotine-containing solution: case report and review of the literature. Forensic Sci Int 2010; 195:e19.</a></li><li><a class="nounderline abstract_t">Govindarajan P, Spiller HA, Casavant MJ, et al. E-Cigarette and Liquid Nicotine Exposures Among Young Children. Pediatrics 2018; 141.</a></li><li><a class="nounderline abstract_t">Vakkalanka JP, Hardison LS Jr, Holstege CP. Epidemiological trends in electronic cigarette exposures reported to U.S. Poison Centers. Clin Toxicol (Phila) 2014; 52:542.</a></li><li><a class="nounderline abstract_t">Maessen GC, Wijnhoven AM, Neijzen RL, et al. Nicotine intoxication by e-cigarette liquids: a study of case reports and pathophysiology. Clin Toxicol (Phila) 2020; 58:1.</a></li><li><a class="nounderline abstract_t">Wang Y, Yang M, Huang Z, et al. Urinary cotinine concentrations in preschool children showed positive associations with smoking fathers. Acta Paediatr 2017; 106:67.</a></li><li><a class="nounderline abstract_t">Corkery JM, Button J, Vento AE, Schifano F. Two UK suicides using nicotine extracted from tobacco employing instructions available on the Internet. Forensic Sci Int 2010; 199:e9.</a></li><li><a class="nounderline abstract_t">Kamble A, Khairkar P, Kalantri SP, Babhulkar S. Fatal Suicidal Attempt by Deliberate Ingestion of Nicotine-containing Solution in Childhood-onset Depression Mediated through Internet Suicide Guideline: A Case Report. Indian J Crit Care Med 2020; 24:719.</a></li><li><a class="nounderline abstract_t">Froberg B, Ibrahim D, Furbee RB. Plant poisoning. Emerg Med Clin North Am 2007; 25:375.</a></li><li><a class="nounderline abstract_t">West PL, Horowitz BZ, Montanaro MT, Lindsay JN. Poison hemlock-induced respiratory failure in a toddler. Pediatr Emerg Care 2009; 25:761.</a></li><li><a class="nounderline abstract_t">Schep LJ, Slaughter RJ, Beasley DM. Nicotinic plant poisoning. Clin Toxicol (Phila) 2009; 47:771.</a></li><li><a class="nounderline abstract_t">Houchat JN, Cartereau A, Le Mauff A, et al. An Overview on the Effect of Neonicotinoid Insecticides on Mammalian Cholinergic Functions through the Activation of Neuronal Nicotinic Acetylcholine Receptors. Int J Environ Res Public Health 2020; 17.</a></li><li><a class="nounderline abstract_t">Connolly GN, Richter P, Aleguas A Jr, et al. Unintentional child poisonings through ingestion of conventional and novel tobacco products. Pediatrics 2010; 125:896.</a></li><li><a class="nounderline abstract_t">Mensch AR, Holden M. Nicotine overdose from a single piece of nicotine gum. Chest 1984; 86:801.</a></li><li><a class="nounderline abstract_t">Woolf A, Burkhart K, Caraccio T, Litovitz T. Childhood poisoning involving transdermal nicotine patches. Pediatrics 1997; 99:E4.</a></li><li><a class="nounderline abstract_t">Mayer B. How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century. Arch Toxicol 2014; 88:5.</a></li><li><a class="nounderline abstract_t">Maina G, Castagnoli C, Passini V, et al. Transdermal nicotine absorption handling e-cigarette refill liquids. Regul Toxicol Pharmacol 2016; 74:31.</a></li><li><a class="nounderline abstract_t">Woolf A, Burkhart K, Caraccio T, Litovitz T. Self-poisoning among adults using multiple transdermal nicotine patches. J Toxicol Clin Toxicol 1996; 34:691.</a></li><li><a class="nounderline abstract_t">Gehlbach SH, Williams WA, Perry LD, Woodall JS. Green-tobacco sickness. An illness of tobacco harvesters. JAMA 1974; 229:1880.</a></li><li><a class="nounderline abstract_t">Fotedar S, Fotedar V. Green Tobacco Sickness: A Brief Review. Indian J Occup Environ Med 2017; 21:101.</a></li><li><a class="nounderline abstract_t">Hughes A, Hendrickson RG. An epidemiologic and clinical description of e-cigarette toxicity. Clin Toxicol (Phila) 2019; 57:287.</a></li><li><a class="nounderline abstract_t">Forrester MB. Pediatric Exposures to Electronic Cigarettes Reported to Texas Poison Centers. J Emerg Med 2015; 49:136.</a></li><li class="breakAll">Fernandez D, Soghoian S. Nicotine. In: oldfrank's Toxicologic Emergencies, 11th edition, Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS (Eds), McGraw Hill Education, New York, NY 2019. p.1204.</li><li><a class="nounderline abstract_t">D'Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product. Nicotine Tob Res 2004; 6:63.</a></li><li class="breakAll">Hudson NL, Dotson GS. NIOSH skin notation profile: Nicotine. Centers for Disease Control and Prevention; US Department of Health and Human Services, Cincinnati, OH 2015.</li><li><a class="nounderline abstract_t">Benowitz NL, Chan K, Denaro CP, Jacob P 3rd. Stable isotope method for studying transdermal drug absorption: the nicotine patch. Clin Pharmacol Ther 1991; 50:286.</a></li><li><a class="nounderline abstract_t">Yildiz D. Nicotine, its metabolism and an overview of its biological effects. Toxicon 2004; 43:619.</a></li><li><a class="nounderline abstract_t">Knudsen K, Strinnholm M. A case of life-threatening rectal administration of moist snuff. Clin Toxicol (Phila) 2010; 48:572.</a></li><li><a class="nounderline abstract_t">Faulkner JM. Nicotine poisoning by absorption through the skin. J Am Med Assoc 1933; 100:1664.</a></li><li><a class="nounderline abstract_t">Frasch HF, Barbero AM. In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment. J Expo Sci Environ Epidemiol 2017; 27:618.</a></li><li><a class="nounderline abstract_t">Taghavi S, Khashyarmanesh Z, Moalemzadeh-Haghighi H, et al. Nicotine content of domestic cigarettes, imported cigarettes and pipe tobacco in iran. Addict Health 2012; 4:28.</a></li><li class="breakAll">Nicorette Gum. https://www.nicorette.com/products/nicorette-gum.html (Accessed on January 15, 2021).</li><li><a class="nounderline abstract_t">Wadgave U, Nagesh L. Nicotine Replacement Therapy: An Overview. Int J Health Sci (Qassim) 2016; 10:425.</a></li><li><a class="nounderline abstract_t">Tjoncke JA, Goncalves R, Castaing N, et al. Death related to nicotine replacement therapy: A case report. Forensic Sci Int 2020; 309:110223.</a></li><li><a class="nounderline abstract_t">Djordjevic MV, Doran KA. Nicotine content and delivery across tobacco products. Handb Exp Pharmacol 2009; :61.</a></li><li><a class="nounderline abstract_t">Anderson MJ, Kurtycz DF, Cline JR. Baptisia poisoning: a new and toxic look-alike in the neighborhood. J Emerg Med 2015; 48:39.</a></li><li><a class="nounderline abstract_t">Perananthan V, Mohamed F, Shahmy S, et al. The clinical toxicity of imidacloprid self-poisoning following the introduction of newer formulations. Clin Toxicol (Phila) 2021; 59:347.</a></li><li><a class="nounderline abstract_t">Sriapha C, Trakulsrichai S, Tongpoo A, et al. Acute Imidacloprid Poisoning in Thailand. Ther Clin Risk Manag 2020; 16:1081.</a></li><li><a class="nounderline abstract_t">Sriapha C, Trakulsrichai S, Intaraprasong P, et al. Imidacloprid poisoning case series: potential for liver injury. Clin Toxicol (Phila) 2020; 58:136.</a></li><li><a class="nounderline abstract_t">Kamboj A, Spiller HA, Casavant MJ, et al. Pediatric Exposure to E-Cigarettes, Nicotine, and Tobacco Products in the United States. Pediatrics 2016; 137.</a></li><li class="breakAll">National Institute for Occupational Safety and Health. Nicotine: Systemic Agent. https://www.cdc.gov/niosh/ershdb/EmergencyResponseCard_29750028.html (Accessed on January 15, 2021).</li><li><a class="nounderline abstract_t">Smolinske SC, Spoerke DG, Spiller SK, et al. Cigarette and nicotine chewing gum toxicity in children. Hum Toxicol 1988; 7:27.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Ingestion of cigarettes and cigarette butts by children--Rhode Island, January 1994-July 1996 . MMWR Morb Mortal Wkly Rep 1997; 46:125.</a></li><li><a class="nounderline abstract_t">Sommerfeld K, Łukasik-Głębocka M, Kulza M, et al. Intravenous and oral suicidal e-liquid poisonings with confirmed nicotine and cotinine concentrations. Forensic Sci Int 2016; 262:e15.</a></li><li><a class="nounderline abstract_t">Bartschat S, Mercer-Chalmers-Bender K, Beike J, et al. Not only smoking is deadly: fatal ingestion of e-juice-a case report. Int J Legal Med 2015; 129:481.</a></li><li><a class="nounderline abstract_t">Raja M, Garg A, Yadav P, et al. Diagnostic Methods for Detection of Cotinine Level in Tobacco Users: A Review. J Clin Diagn Res 2016; 10:ZE04.</a></li><li><a class="nounderline abstract_t">Martínez-Sánchez JM, González-Marrón A, Martín-Sánchez JC, et al. Validity of self-reported intensity of exposure to second-hand smoke at home against environmental and personal markers. Gac Sanit 2018; 32:393.</a></li><li><a class="nounderline abstract_t">Zwiener RJ, Ginsburg CM. Organophosphate and carbamate poisoning in infants and children. Pediatrics 1988; 81:121.</a></li><li><a class="nounderline abstract_t">Mills KC, Curry SC. Acute iron poisoning. Emerg Med Clin North Am 1994; 12:397.</a></li><li><a class="nounderline abstract_t">McBride JS, Altman DG, Klein M, White W. Green tobacco sickness. Tob Control 1998; 7:294.</a></li><li><a class="nounderline abstract_t">McKnight RH, Spiller HA. Green tobacco sickness in children and adolescents. Public Health Rep 2005; 120:602.</a></li><li><a class="nounderline abstract_t">Weizenecker R, Deal WB. Tobacco cropper's sickness. J Fla Med Assoc 1970; 57:13.</a></li><li><a class="nounderline abstract_t">Swinker M, Meredith JT. A seizure in the tobacco field. Green tobacco sickness. N C Med J 2000; 61:390.</a></li><li><a class="nounderline abstract_t">Ballard T, Ehlers J, Freund E, et al. Green tobacco sickness: occupational nicotine poisoning in tobacco workers. Arch Environ Health 1995; 50:384.</a></li></ol></div><div id="topicVersionRevision">Topic 130609 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890263" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19954906" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Death due to ingestion of nicotine-containing solution: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29686144" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : E-Cigarette and Liquid Nicotine Exposures Among Young Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24792781" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiological trends in electronic cigarette exposures reported to U.S. Poison Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31286797" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nicotine intoxication by e-cigarette liquids: a study of case reports and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27748973" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Urinary cotinine concentrations in preschool children showed positive associations with smoking fathers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202767" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Two UK suicides using nicotine extracted from tobacco employing instructions available on the Internet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33024383" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fatal Suicidal Attempt by Deliberate Ingestion of Nicotine-containing Solution in Childhood-onset Depression Mediated through Internet Suicide Guideline: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482026" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Plant poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915429" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Poison hemlock-induced respiratory failure in a toddler.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19778187" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nicotinic plant poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32384754" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An Overview on the Effect of Neonicotinoid Insecticides on Mammalian Cholinergic Functions through the Activation of Neuronal Nicotinic Acetylcholine Receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20403932" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Unintentional child poisonings through ingestion of conventional and novel tobacco products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6488931" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nicotine overdose from a single piece of nicotine gum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9113961" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Childhood poisoning involving transdermal nicotine patches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24091634" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26619784" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transdermal nicotine absorption handling e-cigarette refill liquids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8941198" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Self-poisoning among adults using multiple transdermal nicotine patches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4479133" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Green-tobacco sickness. An illness of tobacco harvesters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29618907" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Green Tobacco Sickness: A Brief Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30306801" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An epidemiologic and clinical description of e-cigarette toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25802158" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pediatric Exposures to Electronic Cigarettes Reported to Texas Poison Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25802158" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pediatric Exposures to Electronic Cigarettes Reported to Texas Poison Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982689" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982689" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1914363" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Stable isotope method for studying transdermal drug absorption: the nicotine patch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15109883" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nicotine, its metabolism and an overview of its biological effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20560789" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A case of life-threatening rectal administration of moist snuff.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nicotine poisoning by absorption through the skin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27924817" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : In vitro human epidermal permeation of nicotine from electronic cigarette refill liquids and implications for dermal exposure assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24494133" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nicotine content of domestic cigarettes, imported cigarettes and pipe tobacco in iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24494133" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Nicotine content of domestic cigarettes, imported cigarettes and pipe tobacco in iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27610066" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nicotine Replacement Therapy: An Overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32146302" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Death related to nicotine replacement therapy: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19184646" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nicotine content and delivery across tobacco products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25453859" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Baptisia poisoning: a new and toxic look-alike in the neighborhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32959700" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The clinical toxicity of imidacloprid self-poisoning following the introduction of newer formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33204096" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Acute Imidacloprid Poisoning in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31092066" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Imidacloprid poisoning case series: potential for liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27244861" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pediatric Exposure to E-Cigarettes, Nicotine, and Tobacco Products in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27244861" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pediatric Exposure to E-Cigarettes, Nicotine, and Tobacco Products in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3346035" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cigarette and nicotine chewing gum toxicity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9045041" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ingestion of cigarettes and cigarette butts by children--Rhode Island, January 1994-July 1996 .</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27020616" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intravenous and oral suicidal e-liquid poisonings with confirmed nicotine and cotinine concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25239221" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Not only smoking is deadly: fatal ingestion of e-juice-a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27135020" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Diagnostic Methods for Detection of Cotinine Level in Tobacco Users: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29102505" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Validity of self-reported intensity of exposure to second-hand smoke at home against environmental and personal markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336578" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Organophosphate and carbamate poisoning in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8187690" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute iron poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9825425" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Green tobacco sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16350329" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Green tobacco sickness in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5490388" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Tobacco cropper's sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10647256" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A seizure in the tobacco field. Green tobacco sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7574894" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Green tobacco sickness: occupational nicotine poisoning in tobacco workers.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
